RxSight, Inc. (RXST) Posts Fourth Quarter Loss, Surpasses Revenue Expectations

RxSight, Inc. (RXST) Reports Quarterly Results

RxSight, Inc. (RXST) announced a quarterly per-share loss of $0.03, which was significantly better than the anticipated loss of $0.23 according to Zacks Consensus Estimate. In the same period last year, the company reported earnings of $0.03 per share. These numbers are adjusted to exclude one-time items.

This quarter's results reflect a positive earnings surprise of 87.14%. In the previous quarter, the company was expected to post a loss of $0.19 per share but instead reported a smaller loss of $0.04, resulting in a surprise of 78.95%.

For the past four quarters, RxSight has consistently exceeded consensus EPS projections.

Operating within the Medical - Instruments sector as classified by Zacks, RxSight generated $32.61 million in revenue for the quarter ending December 2025, narrowly beating the consensus estimate by 0.02%. This is a decrease from the $40.21 million reported in the same quarter last year. The company has outperformed revenue expectations for four consecutive quarters.

The immediate impact on RxSight's share price will likely hinge on management's insights and guidance provided during the earnings call.

Since the start of the year, RxSight's stock has declined by approximately 14.2%, while the S&P 500 has seen a modest increase of 0.7%.

What Lies Ahead for RxSight?

Although RxSight has lagged behind the broader market this year, investors are now considering the company's future prospects.

While there is no definitive answer, one useful indicator is the company's earnings outlook, which includes both current consensus forecasts for upcoming quarters and recent changes to those estimates.

Studies have demonstrated a strong link between short-term stock performance and trends in earnings estimate revisions. Investors can monitor these changes independently or utilize established rating systems such as the Zacks Rank, which has a proven history of leveraging earnings estimate trends.

Prior to this earnings announcement, analyst estimate revisions for RxSight were negative. Although these revisions may shift following the latest results, the current outlook gives RxSight a Zacks Rank #4 (Sell), suggesting the stock may underperform the market in the near term. For a full list of Zacks #1 Rank (Strong Buy) stocks, click here.

It will be important to observe how analyst estimates for the next quarters and the current fiscal year evolve in the coming days. Presently, the consensus EPS forecast stands at -$0.09 on $31.78 million in revenue for the next quarter, and -$0.30 on $135.46 million in revenue for the full fiscal year.

Investors should also consider the broader industry outlook, as it can significantly influence individual stock performance. The Medical - Instruments sector currently ranks in the top 30% among more than 250 Zacks industries. Research indicates that the top half of Zacks-ranked industries outperform the bottom half by more than two to one.

Another company in the same industry, Sight Sciences, Inc. (SGHT), has yet to release its results for the quarter ending December 2025, with the report expected on March 4.

Sight Sciences is projected to report a quarterly loss of $0.17 per share, reflecting a 26.1% improvement year-over-year. Over the past month, the consensus EPS estimate for this quarter has increased by 2.4%.

The company’s revenue is anticipated to reach $20.27 million, which would be a 6.3% increase compared to the same period last year.

Is RxSight, Inc. (RXST) a Good Investment?

Before making an investment decision regarding RxSight, Inc. (RXST), you may want to explore the top stock picks for the next month. Zacks Investment Research offers a complimentary report on the 7 best stocks to buy now.

Since 1978, Zacks Investment Research has provided investors with independent analysis and tools. Over more than 25 years, the Zacks Rank stock-rating system has delivered average annual returns of 24.08%, more than doubling the S&P 500’s performance from January 1, 1988, through May 6, 2024.

Interested in the latest stock recommendations from Zacks Investment Research? Download the 7 Best Stocks for the Next 30 Days for free.